Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1737P - Prognosis of metastatic sites in heart-specific death of cancer patients

Date

16 Sep 2021

Session

ePoster Display

Topics

Cancer Prevention

Tumour Site

Thoracic Malignancies

Presenters

Mohammed Hussein Omar Safi

Citation

Annals of Oncology (2021) 32 (suppl_5): S1199-S1204. 10.1016/annonc/annonc730

Authors

M.H.O. Safi1, M. Al-azab2, X. Shan3, A. Wang4, C. Jin4, Q. Henan4, J. Liu5

Author affiliations

  • 1 Thoracic Oncology Department, First affiliated hospital of Dalian medical university, 116044 - Dalian/CN
  • 2 Immunology, Guangzhou medical unviersity, 510182 - Guangzhou/CN
  • 3 Thoracic Oncology Departmet, The first affiliated hospital of Dalian medical university, 0086 - Dalian city/CN
  • 4 Department thoracic Oncology Department, First affiliated hospital of Dalian Medical University, 000 - Dalian/CN
  • 5 Thoracic Oncology Departmet, The first affiliated hospital of Dalian medical university, 116044 - Dalian city/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1737P

Background

The range of cardiovascular risks in cancer patients is diverse. Patients with metastatic/distant illness at the time of diagnosis have the highest standard mortality rate of fatal heart attack than do regional and localized staged patients. We wanted to investigate the pattern of distant sites (bone, brain, liver, and lung metastases) and subsequent survival of patients with heart-related deaths from all cancer forms.

Methods

We conducted a Surveillance, Epidemiology, and End Results (SEER) registry-based investigation (2010-2016) and collected data on cancer patients with advanced stages who died from cardiac events. For survival analysis, the Kaplan-Meier technique was used, and a multivariate model was created by controlling for multiple confounding factors.

Results

We extracted 6021 distant cancer patients who experienced fatal heart death. Distant lung cancer was predominantly seen with a higher percentage of fatal heart attack rate than orodigestive tract and bone marrow (33.7%, 19%, 16.2%). In the study difference of survival between the metastatic sites in lung, the liver metastasis reveals worse survival than others (p=>0.0001; median months: 2 vs. 1 month). Further adjusted variables by multivariate model, the lung metastases showed favorable survival than liver mets site (P=<0.000, 1.395(1.244-1.564).

Conclusions

Most cases of metastasis in heart-specific death patients were reported in lung cancer sites. While liver metastasis was associated with worse prognosis, the metastasis to lung was related to greater survival than other metastatic locations. More research is needed to predict the prognosis of distant patients and the related cardiac morbidity and mortality.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.